Related Experiment Videos
Relationship between an 85 kDa protein and the protective effects of Mycoplasma pneumoniae
M Yayoshi1, T Sasaki, M Yoshioka
1Urawa Gakuin, Urawa, Saitama, Japan.
Abstract:
In the immunoblot analysis, sera from patients infected with Mycoplasma pneumoniae reacted with the 168 kDa (P1) and the 85 kDa proteins of virulent strain FH-P24 and P24-S1 mutant strain but not with the 85 kDa protein of P24-S11. Sera of hamsters and BALB/c mice, which had been immunized with live vaccines, were tested. In FH-P24 immunized animals, 100% or 80%, and in P24-S1, 40% of hamsters and 60% of BALB/c mice, developed antibodies against the 85 kDa protein, but antibodies were not detected in sera of P24-S11 immunized animals. The correlation between the development of antibodies to 85 kDa protein in the sera of vaccinated animals and the effects of protection by living vaccines were suggested.
Insights
Antibodies against Mycoplasma pneumoniae's 85 kDa protein were detected in vaccinated animals, suggesting a correlation with protection. This finding is crucial for developing effective vaccines against this pathogen.
Area of Science:
- Immunology
- Microbiology
- Vaccinology
Background:
- Mycoplasma pneumoniae is a significant human pathogen causing respiratory infections.
- Understanding host immune responses to Mycoplasma pneumoniae antigens is crucial for vaccine development.
- The P1 protein (168 kDa) and an 85 kDa protein are key antigens of Mycoplasma pneumoniae.
Purpose of the Study:
- To investigate the immunogenicity of Mycoplasma pneumoniae proteins, specifically the 85 kDa protein, in response to live vaccines.
- To assess the correlation between antibody development against the 85 kDa protein and protective effects in vaccinated animal models.
Main Methods:
- Immunoblot analysis was performed using sera from Mycoplasma pneumoniae-infected patients and vaccinated animals (hamsters and BALB/c mice).
- Vaccines tested included virulent strain FH-P24 and mutant strains P24-S1 and P24-S11.
- Antibody detection against specific Mycoplasma pneumoniae proteins (168 kDa and 85 kDa) was quantified.
Main Results:
- Sera from infected patients reacted with 168 kDa (P1) and 85 kDa proteins of virulent and P24-S1 strains, but not the 85 kDa protein of P24-S11.
- Vaccination with FH-P24 induced antibodies against the 85 kDa protein in 100% (hamsters) or 80% (mice) of animals.
- Vaccination with P24-S1 induced antibodies in 40% (hamsters) and 60% (mice), while P24-S11 induced no detectable antibodies.
Conclusions:
- The 85 kDa protein is immunogenic and elicits antibody responses in vaccinated animals.
- A strong correlation was observed between the development of antibodies to the 85 kDa protein and the protective efficacy of live Mycoplasma pneumoniae vaccines.
- These findings highlight the potential of the 85 kDa protein as a target antigen for future Mycoplasma pneumoniae vaccine development.